Summary for sequencing therapies for recurrent classic HL

Patients whose disease recurs who have not received brentuximab vedotin or a checkpoint inhibitor should consider the combination of nivolumab and brentuximab vedotin.[26,60]

The combination of pembrolizumab plus ICE chemotherapy,[6] nivolumab plus ICE chemotherapy,[14] or pembrolizumab plus GVD chemotherapy [7] is an effective induction therapy prior to autologous SCT.

Consider allogeneic SCT for patients with primary refractory disease who achieved partial response or complete remission on salvage therapy.

Checkpoint inhibitors alone are useful palliative agents for older patients or patients with comorbidities that preclude SCT.